Patent · US Active

Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors

US11052138B2 · kind B2 · utility

2Cited by
13References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 5, 2018
Grant dateJul 6, 2021
Priority date
Expiry dateOct 5, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/03
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A nucleic acid encoding a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) operatively linked to a signaling domain that polarizes a macrophage to an M1 macrophage; wherein the nucleic acid is operatively linked to a macrophage specific promoter; and wherein the scFv is specific for a human antigen. Monocytes or macrophages comprising such a nucleic acid.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.